Memorial Sloan Kettering medical oncologist William Johnson

William Johnson, DO

Lymphoma Specialist & Cellular Therapist

My Role at MSK

Areas of Expertise

My Specialties

  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
English
Share

About Me

What I Do at MSK
  • Assistant Attending Physician
Get To Know Me

I am a board-certified medical oncologist trained in both hematology and medical oncology. My focus is on caring for people with lymphoma who are admitted to the hospital. I oversee the care of people who have recently received a lymphoma diagnosis, patients needing lymphoma therapy in the hospital setting, and those who have been admitted for any other reason associated with their lymphoma. I work closely with the entire team of lymphoma specialists, both within the Department of Medicine and across other departments. At MSK, we emphasize this team approach in order to provide the best care for our patients. My goal is to make your hospital stay as pleasant, seamless, and stress-free as possible.

My Role at MSK

A lymphoma specialist is a doctor with special training in diagnosing and treating lymphoma.

A cellular therapy specialist is a doctor with special training in using cell therapies to treat health conditions such as cancer. Therapies can include chimeric antigen receptor (CAR) T cell therapy.

Areas of Expertise

My Specialties

  • Lymphoma
  • Non-Hodgkin Lymphoma
  • Hodgkin Lymphoma
  • T Cell Lymphoma
  • Cutaneous T Cell lymphoma
  • Chronic Lymphocytic Leukemia
  • Mantle Cell Lymphoma
  • Follicular Lymphoma
  • Diffuse Large B-cell Lymphoma
  • Burkitt Lymphoma
  • Marginal Zone Lymphoma
Education & Honors

Education

  • DO, The Philadelphia College of Osteopathic Medicine

Residencies

  • Internal Medicine - Lankenau Medical Center

Fellowships

  • Hematology and Medical Oncology - Thomas Jefferson University

Board Certifications

  • Internal medicine
  • Hematology
  • Medical Oncology

Insurance Information

Understanding your insurance options is an important part of managing your cancer care. We have relationships with many common healthcare providers and plans.

Aetna

In Network Coverage Type
HMO, EPO PPO, POS, Transplant

Aetna Medicare Advantage (MTA retirees only)

In Network Coverage Type
PPO

Blue Cross Blue Shield Federal Employee Program

In Network Coverage Type
HMO, PPO

Blue Cross Blue Shield New York

In Network Coverage Type
PPO, POS, EPO, HMO

Blue Cross Blue Shield states outside of NY/NJ

In Network Coverage Type
HMO, EPO PPO, POS

Blue Cross Health Plus

In Network Coverage Type
HMO

Carrum Health

In Network Coverage Type
Supplemental

Cigna

In Network Coverage Type
PPO, POS, HMO

Connecticare

In Network Coverage Type
POS, EPO, HMO

Emblem

In Network Coverage Type
PPO, POS, EPO, HMO

Offers a qualified health plan from the Health Insurance Marketplace. Call Emblem to learn more.

Emblem Essential

In Network Coverage Type
HMO

Emblem Medicare Advantage

In Network Coverage Type
PPO, HMO

Empire Blue Cross Medicare Advantage

In Network Coverage Type
PPO, HMO, DSN

Empire Essential

In Network Coverage Type
HMO

Empire Plan / NYSHIP (Blue Cross/UnitedHealthcare split plan)

In Network Coverage Type
PPO

Fidelis

In Network Coverage Type
HMO, EPO

Offers a qualified health plan from the Health Insurance Marketplace. Call Fidelis to learn more.

Fidelis Managed Medicaid & HARP

In Network Coverage Type
HMO

Fidelis Medicare Advantage

In Network Coverage Type
HMO

First Health

In Network Coverage Type
PPO

Healthfirst

In Network Coverage Type
EPO, HMO, PPO, POS

Offers a qualified health plan from the Health Insurance Marketplace. Call Healthfirst to learn more.

Healthfirst Managed Medicaid

In Network Coverage Type
HMO

Healthfirst Medicare Advantage

In Network Coverage Type
HMO, PPO

Healthsmart

In Network Coverage Type
PPO EPO

Horizon Blue Cross Blue Shield New Jersey (HMO)

In Network Coverage Type
HMO

Horizon Blue Cross Blue Shield New Jersey (PPO)

In Network Coverage Type
PPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier I (EPO)

In Network Coverage Type
EPO

Horizon Blue Cross Blue Shield New Jersey Omnia Tier II (EPO)

In Network Coverage Type
EPO

Horizon Medicare Advantage

In Network Coverage Type
PPO, HMO

Husky CT Medicaid

In Network Coverage Type
State Government

Magnacare

In Network Coverage Type
PPO, POS, EPO

Straight NJ Medicaid

In Network Coverage Type
State Government

Straight NY Medicaid

In Network Coverage Type
State Government

Medicare Part A&B (traditional Medicare)

In Network Coverage Type
Federal Government

Multiplan/Beech Street/PHCS

In Network Coverage Type
Supplemental

MVP

In Network Coverage Type
PPO/OAP

Non-Participating Plans with Out of Network Benefits

In Network Coverage Type
PPO, POS, EPO, HMO

NYC Medicare Advantage Plus for City Employees

In Network Coverage Type
TBD

Oscar

In Network Coverage Type
HMO/EPO

Oxford

In Network Coverage Type
PPO, EPO

World Trade Center Health Program (WTC)

In Network Coverage Type
State Government

Qualcare

In Network Coverage Type
PPO, POS, HMO

Tricare

In Network Coverage Type
PPO, HMO

UMR

In Network Coverage Type
PPO, POS

United Healthcare

In Network Coverage Type
PPO, POS, HMO

Don't see your carrier or plan? We can help you understand your coverage.

If you don't have health insurance or are worried that your care may not be fully covered, our financial assistance programs may be able to help.

If you have questions about insurance, call us at 646-497-9176.

Contact and Location

Dr. Johnson sees patients at two locations.

Location
New York, NY

Looking to see a doctor at a different location? See all MSK locations.

Colleagues

Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.

See all Cellular Therapy Service doctors

See all Lymphoma Service doctors

Clinical Trials

Smiling doctors in the lab
Find a Clinical Trial for You

Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.

You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.

Search clinical trials

Research and Publications

Johnson WT, Bharel S, Klumpp T, et al. Impaired CD4+ T-Cell Recovery After Autologous Stem Cell Transplantation. Transplantation and Cellular Therapy. February 2020. 

Johnson WT, Mishra A. The EZ-riding NK/T-cell Lymphoma. Blood commentary on “MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/T-cell lymphoma.” Blood, 2019;134(23):1999-2000. DOI: 10.1182/blood.2019003023.

Johnson WT, Kartan S, Nikbakht N, Porcu P. A Prospective Cohort of Black Patients with Mycosis Fungoides and Sézary Syndrome: Subset Analysis of the Mavoric Trial.  American Society of Hematology. December 2019.

Johnson WT, Mishra A, Binder A, Gru A, Porcu P. Mogamulizumab versus Investigator’s Choice in Relapsed/Refractory Adult T-Cell Leukemia/Lymphoma: All Four One or None for All? Editorial on “Mogamulizumab versus Investigator’s Choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma.” Haematologica, 2019;104(5):864-67. DOI: 10.3324/haematol.2018.214536.

Read more

Johnson WT, Garfunkle D, Misung Y, et al. Outcomes of Methotrexate-associated T-cell and NK/T-cell Lymphoproliferative Disorders in Patients with a History of Rheumatological Disorders: A Retrospective Analysis of EBV-association and Response to MTX Withdrawal. Society of Hematologic Oncology. September 2019.

Johnson WT, Mukherji R, Kartan S, Nikbakht N, Porcu P, Alpdogan O. Allogeneic Hematopoietic Stem Cell Transplantation in Advanced Stage Mycosis Fungoides and Sézary Syndrome: A Concise Review. Chinese Clin Oncol, 2019;8(1). DOI: 10.21037/cco.2018.10.03.

Alpdogan O, Kartan S, Johnson WT, Sokol K, Porcu P. Systemic Therapy for Cutaneous T-cell Lymphoma (CTCL). Chinese Clin Oncol, 2019;8(1). DOI: 10.21037/cco.2019.01.02.

Kartan S, Johnson WT, Sokol K, Alpdogan O, Gru AA, Nikbakht N, Porcu P. The Spectrum of CD30+ T-cell Lymphoproliferative Disorders in the Skin. Chinese Clin Oncol, 2019;8(1). DOI: 10.21037/cco.2018.12.03.

Sokol K, Kartan S, Johnson WT, et al. Extreme Peripheral Blood Plasmacytosis Mimicking Plasma Cell Leukemia as a Presenting Feature of Angioimmunoblastic T-Cell Lymphoma (AITL). Front Oncol, 2019;9:509. DOI: 10.3389/fonc.2019.00509. 

Johnson WT, Patel P, Hernandez A, et al. Langerhans Cell Histiocytosis and Erdheim-Chester Disease, both with Cutaneous Presentations, and Papillary Thyroid Carcinoma All Harboring the BRAFV600E Mutation. J Cutan Pathol, 2016;43(3): 270–75. DOI: 10.1111/cup.12636.

Johnson WT, Leeman-Neil R, Patel P. A Fatal Case of Primary Cutaneous Aggressive T-cell Lymphoma Switching from a CD4+ to a CD8+ Phenotype: Progressive Disease with Bexarotene and Romidepsin Treatment. Am J Dermatopath, 2016;38(11):832–37. DOI: 10.1097/DAD.0000000000000609.

Disclosures

Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

William Johnson discloses the following relationships and financial interests:

  • Myeloid Therapeutics Inc.
    Professional Services and Activities

If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.


This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures